carboplatin + etoposide

DRUG4 trials

Sponsors

Gustave Roussy, Cancer Campus, Grand Paris, AstraZeneca, Haihe Biopharma Co., Ltd., Phanes Therapeutics

Conditions

Carcinoma, Pancreatic DuctalCarcinoma, Squamous Cell of Head and NeckEsophageal Squamous Cell CarcinomaEsophagogastric Junction NeoplasmsExtensive-stage Small Cell Lung CancerExtrapulmonary Neuroendocrine Carcinoma (EP-NEC)Fallopian Tube NeoplasmsGastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Phase 1

Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma

TerminatedNCT02025881

Gustave Roussy, Cancer Campus, Grand ParisHigh-risk Medulloblastoma

Start: 2013-09-14End: 2020-10-25Updated: 2024-05-24

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

CompletedNCT02658214

AstraZenecaCarcinoma, Pancreatic Ductal, Carcinoma, Squamous Cell of Head and Neck, Esophageal Squamous Cell Carcinoma +7

Start: 2016-04-28End: 2019-11-14Updated: 2020-08-20

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

RecruitingNCT05652686

Phanes TherapeuticsExtrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Large Cell Neuroendocrine Cancer (LCNEC) +3

Start: 2023-09-05End: 2028-08-31Target: 203Updated: 2025-09-23

Phase 2

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Haihe Biopharma Co., Ltd.Extensive-stage Small Cell Lung Cancer

Start: 2019-11-14End: 2022-11-22Target: 313Updated: 2020-02-05

Related Papers

An open-label, multicenter, phase 1/2 study of peluntamig (PT217), an anti-DLL3/anti-CD47 bispecific antibody, in patients with DLL3-expressing cancers such as SCLC, LCNEC and EP-NEC (SKYBRIDGE study).

Journal of Clinical Oncology2025-05-281 citations

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

Cancer Medicine2023-07-255 citations

Evaluation of safety and tolerability of durvalumab (D) and tremelimumab (T) in combination with first-line chemotherapy in patients (pts) with esophageal squamous-cell carcinoma (ESCC).

Journal of Clinical Oncology2019-01-299 citations